

**Guidelines for the Reversal of the New Anticoagulants in the Setting of Life-threatening or Major Bleeding
Kingston General Hospital**

**Management of Bleeding Patient Receiving Direct Anti Xa agents:
Rivaroxaban (Xarelto®), apixaban (Eliquis®)**


Indications for Direct anti-Xa inhibitors:

1. VTE prophylaxis after hip and knee arthroplasty
2. VTE treatment
3. Stroke prevention in patients with atrial fibrillation

Pharmacologic Properties:

	Rivaroxaban	Apixaban
• Peak level	2-4 hours	1-2 hours
• Clearance		
- Renal	33%	25%
- liver	33%	75%
• Dosing	Once daily	Twice Daily
• Half-life	9-12 hours	8-15 hours

Assessment of Bleeding Patients Receiving anti-Xa inhibitors



1. **DO NOT TRANSFUSE FP to reverse ↑ aPTT.**
2. **Do not request FVIIa** – currently no role for this product.

References:

1. Marks et al. Thrombosis Hemostasis 2012; epub May 25
2. American J. of Hematology 2012 THSNA meeting proceeding.